| abstract |
The invention belongs to the technical field of medicine, and relates to the new use of κ-opioid receptor agonist U50,488H, more specifically, to the use of κ-opioid receptor agonist U50,488H in the preparation of medicines for treating vascular calcification. It has been proved by experiments that the mechanism of its inhibition of vascular calcification is: by reducing the expression of PFKFB3, thereby inhibiting the level of glycolysis, thereby inhibiting the calcification of VSMCs induced by high phosphorus, the research results provide a potential drug target for clinical treatment of vascular calcification and treatment strategies. |